{{.infobox .infobox-gene}}
| Symbol | SLC22A3 |
| Full Name | Solute Carrier Family 22 Member 3 (OCT3) |
| Chromosome | 6q27 |
| NCBI Gene ID | 6581 |
| OMIM | 604349 |
| Ensembl ID | ENSG00000149402 |
| UniProt ID | O75727 |
| Associated Diseases | AD, PD, depression, anxiety disorders |
Organic cation transporter 3 (OCT3), also known as the extraneuronal monoamine transporter (EMT), is a polyspecific transmembrane transporter encoded by the SLC22A3 gene on chromosome 6q27[1]. OCT3 belongs to the solute carrier family 22 (SLC22) and mediates the Na⁺-independent transport of organic cations across cell membranes. Unlike neuronal transporters such as the dopamine transporter (DAT, encoded by SLC6A3) that primarily clear neurotransmitters from the synaptic cleft, OCT3 operates in the extraneuronal space to regulate ambient monoamine levels[2].
OCT3 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration and neuropsychiatric disorders.
The SLC22A3 gene spans approximately 32 kb and consists of 11 exons. It encodes a 556-amino acid protein with 12 transmembrane domains (TMDs), characteristic of the major facilitator superfamily. The protein localizes to the plasma membrane and exhibits broad substrate specificity, accepting cationic neurotransmitters, drugs, and endogenous metabolites[1:1].
Key structural features include:
OCT3 is expressed in multiple tissues throughout the body:
| Tissue | Expression Level | Function |
|---|---|---|
| Brain | High | Monoamine clearance, stress response |
| Liver | High | Drug metabolism, toxin clearance |
| Heart | Moderate | Catecholamine handling |
| Skeletal muscle | Moderate | Metabolic regulation |
| Kidney | High | Drug excretion |
In the brain, OCT3 is expressed in:
OCT3 transports the following monoamine neurotransmitters:
Unlike the high-affinity neuronal transporters (DAT, NET, SERT), OCT3 operates with:
This enables OCT3 to regulate ambient extracellular monoamine concentrations beyond the synaptic cleft, contributing to the overall homeostasis of neurotransmission[2:1][3].
A unique feature of OCT3 is its regulation by glucocorticoids. Acute stress elevates corticosterone (in rodents) or cortisol (in humans), which rapidly (within minutes) upregulates OCT3 activity through non-genomic mechanisms[4]. This creates a stress-responsive clearance pathway for monoamines, linking psychological stress to neurotransmitter dynamics.
The molecular pathway involves:
OCT3 plays a crucial role at the blood-brain barrier (BBB), where it contributes to the bidirectional transport of monoamines and drugs between the peripheral circulation and the central nervous system[5]. Unlike the BBB's tight junction barriers that restrict paracellular diffusion, OCT3-mediated transport provides a regulated gateway for specific substrates:
The BBB expression of OCT3 is dynamically regulated by various factors including stress hormones, inflammatory cytokines, and pathological states. In neurodegenerative diseases, BBB dysfunction may alter OCT3 expression and function, contributing to monoaminergic dysregulation.
Recent research has revealed that OCT3 participates in neuroinflammatory processes that are central to neurodegenerative diseases[6]:
In Alzheimer's disease, neuroinflammation drives disease progression, and OCT3 dysfunction may exacerbate inflammatory responses through impaired monoamine clearance. Similarly, in Parkinson's disease, neuroinflammation contributes to dopaminergic neuron loss, where OCT3 may play a protective or pathological role depending on its functional state.
OCT3 exhibits diurnal variation in its expression and activity, contributing to the circadian regulation of monoaminergic neurotransmission:
Disrupted circadian rhythms are a common feature of both Alzheimer's and Parkinson's diseases. The role of OCT3 in circadian regulation suggests that chronotherapeutic approaches targeting monoamine transporters may have therapeutic potential.
OCT3 alterations have been implicated in Alzheimer's disease through several mechanisms:
Monoamine dysregulation hypothesis: AD is associated with progressive monoamine deficiency, particularly in the noradrenergic locus coeruleus system. OCT3 may represent a compensatory mechanism to clear accumulating extracellular monoamines that become neurotoxic at high concentrations.
Oxidative stress: Dopamine oxidation produces reactive oxygen species (ROS). Impaired OCT3 function may lead to increased extracellular dopamine, promoting oxidative damage to neurons—a hallmark of AD pathology.
Glucocorticoid toxicity: Chronic stress and elevated cortisol are risk factors for AD. OCT3 dysregulation may contribute to HPA axis dysregulation and cortisol-mediated neurotoxicity.
Post-mortem studies of AD brains have revealed alterations in SLC22A3 expression[7]:
Targeting OCT3 in AD may provide therapeutic benefits:
OCT3 plays significant roles in PD pathophysiology:
Dopamine homeostasis: OCT3 contributes to extraneuronal dopamine clearance. Genetic variants in SLC22A3 have been associated with PD susceptibility, potentially altering dopamine metabolism in the substantia nigra.
L-DOPA response: OCT3 may influence the pharmacokinetics of L-DOPA, the primary PD treatment, by affecting its distribution and clearance.
Alpha-synuclein interaction: Emerging research suggests monoamine transporters may influence alpha-synuclein (SNCA) aggregation through effects on dopamine metabolism and oxidative stress.
Studies in PD models have demonstrated OCT3 involvement[8]:
OCT3 influences PD therapeutics:
OCT3 is strongly implicated in mood disorders:
OCT3 knockout mice exhibit decreased anxiety-like behavior, indicating a role in anxiety regulation[9].
Genetic associations: Polymorphisms in SLC22A3 have been linked to major depressive disorder and anxiety disorders[10].
Stress response: Dysregulated OCT3 function may contribute to HPA axis dysfunction, a core feature of depression.
Several functional polymorphisms in SLC22A3 have been characterized:
| SNP | Function | Clinical Impact |
|---|---|---|
| rs2048327 | Expression | Altered monoamine transport |
| rs3088442 | Coding (Ala427Ala) | Splicing regulation |
| rs622342 | Expression | Drug response |
Genome-wide association studies (GWAS) have identified SLC22A3 variants in:
OCT3 polymorphisms significantly influence drug response[11]:
Psychotropic drugs:
Antiparkinsonian drugs:
Clinical implications:
OCT3 transports numerous drugs and toxins:
Substrates:
Inhibitors:
Modulating OCT3 activity represents a potential therapeutic strategy:
OCT3 interacts with several proteins and pathways:
OCT3 dysfunction may manifest in specific depression phenotypes:
Atypical depression: Characterized by mood reactivity (mood improves with positive events), increased appetite, and hypersomnia. Altered monoamine clearance could contribute to the baseline elevated mood observed in this subtype.
Melancholic depression: Features include anhedonia, psychomotor retardation, and diurnal variation. OCT3 may influence the monoamine fluctuations underlying these symptoms.
Cortisol rhythm alterations: Many depressed patients show flattened cortisol diurnal rhythm. OCT3, being glucocorticoid-regulated, may contribute to this dysregulation.
Generalized anxiety disorder (GAD): OCT3 variants may influence worry and arousal through effects on norepinephrine clearance in prefrontal cortex.
Panic disorder: Altered monoamine clearance could affect the fight-or-flight response circuitry.
Social anxiety disorder: OCT3 in the amygdala and prefrontal cortex may modulate fear responses.
Motor fluctuations: OCT3 may influence L-DOPA pharmacokinetics, affecting "on-off" fluctuations.
Non-motor symptoms: Depression, anxiety, and fatigue in PD may involve OCT3 dysfunction.
Neuroimaging findings: PET studies using OCT3 substrates could reveal transporter availability in PD brains.
OCT3 is conserved across mammals:
| Species | Ortholog | Similarity |
|---|---|---|
| Human | SLC22A3 | 100% |
| Mouse | Slc22a3 | 92% |
| Rat | Slc22a3 | 91% |
| Zebrafish | slc22a3 | 72% |
OCT3 as a biomarker:
Current and potential therapeutic approaches:
Selective serotonin reuptake inhibitors (SSRIs): Some SSRIs inhibit OCT3, contributing to their mechanism.
Monoamine oxidase inhibitors (MAOIs): Combined with OCT3 function for enhanced monoamine levels.
Novel drug development: Selective OCT3 modulators are in development.
In vitro approaches:
In vivo approaches:
Human studies:
OCT3 as a biomarker for neurodegenerative diseases:
Diagnostic potential:
Disease monitoring:
Research on OCT3 continues to evolve:
Gene therapy approaches: Viral vector-mediated OCT3 overexpression for neuroprotection
Stem cell models: iPSC-derived neurons from patients with SLC22A3 variants
Novel ligands: Development of PET tracers for OCT3 imaging in vivo
Systems biology: Integration of OCT3 data into monoamine network models
Koepsell et al. Polyspecific organic cation transporters: structure, function, physiological roles. J Membr Biol. 2007. ↩︎ ↩︎
Gasser et al. Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. Neuropsychopharmacology. 2008. ↩︎ ↩︎
Bacher et al. General Overview of Organic Cation Transporters in Brain. Handb Exp Pharmacol. 2021. ↩︎
Bacher et al. Organic cation transporter 3: A cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior. Neuropsychopharmacology. 2018. ↩︎
Noll C, et al. OCT3 and the blood-brain barrier. Journal of Cerebral Blood Flow & Metabolism. 2020. ↩︎
Zhang Y, et al. OCT3 in stress-induced neuropsychiatric disorders. Molecular Psychiatry. 2024. ↩︎
Wang L, et al. SLC22A3 in Alzheimer's disease neuropathology. Acta Neuropathologica. 2022. ↩︎
He J, et al. Monoamine transporter dysfunction in PD models. Neurobiology of Disease. 2023. ↩︎
Vialou et al. Decreased anxiety in mice lacking the organic cation transporter 3. Neuropsychopharmacology. 2009. ↩︎
Chen et al. OCT3 polymorphisms and the risk of psychiatric disorders. Neuropsychopharmacology. 2004. ↩︎
Wu X, et al. Polymorphisms of SLC22A3 and drug response. Pharmacogenomics. 2022. ↩︎